...
首页> 外文期刊>Oncogene >Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival
【24h】

Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival

机译:在已建立的恶性神经胶质瘤异种移植物中靶向抑制Hedgehog途径可提高生存率

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Hedgehog pathway activity has been demonstrated in malignant glioma. However, its role in tumor growth has not been determined. Here we demonstrate that pharmacological inhibition of the Hedgehog pathway in established orthotopic malignant glioma xenografts confers a survival advantage. Pathway inhibition is measured in transplanted human tumor cells and not in host mouse brain. Correspondingly, survival benefit is observed only in tumors with an operational Hedgehog pathway. These data indicate that Hedgehog signaling regulates the growth of select malignant gliomas. We also demonstrate that Hedgehog pathway component and gene target expression segregate to CD133+ tumor initiating cells. Treated mice eventually succumb to disease, thus, targeting the Hedgehog pathway in CD133+ cells produces significant, but incomplete tumor regression. Therefore, our studies suggest that more complete tumor regression may require the inclusion of other therapeutic targets, including CD133? cells.
机译:刺猬通路活性已在恶性神经胶质瘤中得到证实。然而,其在肿瘤生长中的作用尚未确定。在这里,我们证明已建立的原位恶性神经胶质瘤异种移植物中刺猬通路的药理抑制作用赋予了生存优势。在移植的人类肿瘤细胞中而不是在宿主小鼠脑中测量途径抑制。相应地,仅在具有可操作的刺猬途径的肿瘤中观察到生存益处。这些数据表明刺猬信号调节某些恶性神经胶质瘤的生长。我们还证明了刺猬通路成分和基因靶标表达分离到CD133 +肿瘤起始细胞。经过治疗的小鼠最终会死于疾病,因此,靶向CD133 +细胞中的Hedgehog途径会产生明显但不完全的肿瘤消退。因此,我们的研究表明,更完全的肿瘤消退可能需要包括其他治疗靶点,包括CD133?细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号